TY - JOUR
T1 - A nuclear phosphoinositide kinase complex regulates p53
AU - Choi, Suyong
AU - Chen, Mo
AU - Cryns, Vincent L.
AU - Anderson, Richard A.
N1 - Funding Information:
We thank Addgene and J. Chen (H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA) for the p53 constructs. We are also grateful to J. L. Persson (Lund University) and K. Fukami (Tokyo University of Pharmacy and Life Sciences) for generously sharing ISA-2011B and the KT10 antibody, respectively. We also thank members of the R.A.A. and V.L.C. laboratories for helpful discussions. This work was supported in part by a National Institutes of Health grant GM114386 (R.A.A.), Department of Defense Breast Cancer Research Program grants W81XWH-17-1-0258 (R.A.A.) and W81XWH-17-1-0259 (V.L.C.) and a grant from the Breast Cancer Research Foundation (V.L.C.).
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - The tumour suppressor p53 (encoded by TP53) protects the genome against cellular stress and is frequently mutated in cancer. Mutant p53 acquires gain-of-function oncogenic activities that are dependent on its enhanced stability. However, the mechanisms by which nuclear p53 is stabilized are poorly understood. Here, we demonstrate that the stability of stress-induced wild-type and mutant p53 is regulated by the type I phosphatidylinositol phosphate kinase (PIPKI-α (also known as PIP5K1A)) and its product phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Nuclear PIPKI-α binds to p53 upon stress, resulting in the production and association of PtdIns(4,5)P2 with p53. PtdIns(4,5)P2 binding promotes the interaction between p53 and the small heat shock proteins HSP27 (also known as HSPB1) and αB-crystallin (also known as HSPB5), which stabilize nuclear p53. Moreover, inhibition of PIPKI-α or PtdIns(4,5)P2 association results in p53 destabilization. Our results point to a previously unrecognized role of nuclear phosphoinositide signalling in regulating p53 stability and implicate this pathway as a promising therapeutic target in cancer.
AB - The tumour suppressor p53 (encoded by TP53) protects the genome against cellular stress and is frequently mutated in cancer. Mutant p53 acquires gain-of-function oncogenic activities that are dependent on its enhanced stability. However, the mechanisms by which nuclear p53 is stabilized are poorly understood. Here, we demonstrate that the stability of stress-induced wild-type and mutant p53 is regulated by the type I phosphatidylinositol phosphate kinase (PIPKI-α (also known as PIP5K1A)) and its product phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Nuclear PIPKI-α binds to p53 upon stress, resulting in the production and association of PtdIns(4,5)P2 with p53. PtdIns(4,5)P2 binding promotes the interaction between p53 and the small heat shock proteins HSP27 (also known as HSPB1) and αB-crystallin (also known as HSPB5), which stabilize nuclear p53. Moreover, inhibition of PIPKI-α or PtdIns(4,5)P2 association results in p53 destabilization. Our results point to a previously unrecognized role of nuclear phosphoinositide signalling in regulating p53 stability and implicate this pathway as a promising therapeutic target in cancer.
UR - http://www.scopus.com/inward/record.url?scp=85064145227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064145227&partnerID=8YFLogxK
U2 - 10.1038/s41556-019-0297-2
DO - 10.1038/s41556-019-0297-2
M3 - Article
C2 - 30886346
AN - SCOPUS:85064145227
VL - 21
SP - 462
EP - 475
JO - Nature Cell Biology
JF - Nature Cell Biology
SN - 1465-7392
IS - 4
ER -